PCOS Renamed PMOS and Here's Everything You Need to Know

For decades, Polycystic Ovary Syndrome (PCOS) has been a widely recognized yet often misunderstood condition affecting millions of women worldwide. However, a century after its name was coined, the disorder is getting a much-needed rebrand. PCOS is now officially known as Polyendocrine Metabolic Ovarian Syndrome (PMOS), a change announced in a recent paper published in The Lancet. This shift reflects a deeper understanding of the condition as a complex endocrine disorder that impacts far more than just the ovaries.

Why the Name Change?

When PCOS was first named, doctors observed what appeared to be cysts on the ovaries of affected women. However, these were not true cysts but rather arrested eggs caused by a broader hormonal imbalance. Over time, research revealed that PCOS affects metabolism, cardiovascular health, skin, and more, with sufferers facing higher risks of Type 2 diabetes, heart disease, and other serious conditions.

Despite this growing body of evidence, the outdated name perpetuated confusion among patients and healthcare providers. Many still associated the condition solely with ovarian cysts, leading to misdiagnosis, delayed treatment, and inadequate care. The renaming to PMOS aims to reframe the disorder as a metabolic and hormonal condition, encouraging a more holistic approach to diagnosis and treatment.

What Changes with PMOS?

The shift from PCOS to PMOS is more than just a name change—it represents a fundamental change in how the condition is perceived and managed.

For years, treatment for PCOS has focused heavily on fertility and reproductive issues, often overlooking its broader health impacts. With the new name, experts hope to prioritize metabolic health, ensuring that patients receive comprehensive care that addresses:

• Metabolic screening for conditions like diabetes and cardiovascular disease.
• Early intervention in adolescents to prevent long-term health complications.

• Expanded treatment options, including medications like GLP-1s, which target metabolic dysfunction.

Additionally, the name change could unlock more research funding and encourage studies beyond reproductive health, addressing the huge health and economic burden of PMOS, which affects 170 million women of reproductive age globally.

How Is PMOS Diagnosed?

The diagnostic criteria for PMOS remain largely the same, but the process is becoming simpler and more accessible. Patients must meet two out of three criteria:

1. Excess male hormones (androgens), which can cause symptoms like acne, hair loss, or excessive hair growth.
2. Irregular menstrual cycles, indicating ovulatory dysfunction.
3. High levels of anti-Müllerian hormone (AMH) in blood tests or the presence of many arrested follicles on an ultrasound.

Interestingly, 60% of women with PMOS only need the first two criteria for diagnosis, eliminating the need for ultrasounds in many cases. For the remaining 30-40%, a blood test may suffice, reducing the reliance on invasive procedures.

What’s Next for PMOS?

The transition from PCOS to PMOS will take time. Over the next three years, the new terminology will be integrated into medical education, clinical guidelines, and research. The ultimate goal is for PMOS to replace PCOS in the International Classification of Diseases (ICD) by 2028, standardizing the name worldwide.

This change is expected to improve patient care, increase awareness, and drive funding for research, ensuring that women with PMOS receive the comprehensive and timely treatment they deserve.

For those affected by PMOS, the new name is more than just a rebrand—it’s a step toward better health outcomes and a brighter future.

This article was previously published on bahrainmoments. To see the original article, click here